Stocktoria
Humacyte, Inc. HUMA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-09-22
Humacyte, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.0M | $0 | — | — | — |
| R&D expense | $69.3M | $88.6M | $76.5M | $63.3M | $61.3M |
| Operating income | -$108.1M | -$114.4M | -$100.0M | -$84.6M | -$81.2M |
| Interest expense | — | — | $6.6M | $6.2M | $4.3M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M | -$26.5M |
| EPS (diluted) | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
| Operating cash flow | -$105.0M | -$98.1M | -$73.3M | -$71.1M | -$81.2M |
| Free cash flow | -$105.9M | -$99.7M | -$75.6M | -$72.2M | -$81.4M |
| Cash & equivalents | $50.5M | $44.9M | $80.4M | $149.8M | $217.5M |
| Inventory | $13.6M | $0 | — | — | — |
| Total assets | $116.4M | $137.9M | $128.2M | $204.3M | $286.5M |
| Total liabilities | $113.3M | $190.5M | $114.7M | $87.4M | $164.4M |
| Shareholders' equity | $3.1M | -$52.7M | $13.5M | $116.9M | $122.2M |
Source: SEC EDGAR filings · CIK 0001818382 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.